Theralugand

Theralugand (Lutetium (177Lu) Chloride) is a radiopharmaceutical used in targeted therapy for certain cancers. This EU-sourced solution supports precision treatment with lutetium-177. Ideal for patients seeking advanced radiotherapeutic options.

Lutetium (177Lu) Chloride is primarily used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer. It delivers localized radiation to cancer cells while minimizing exposure to healthy tissue. This treatment is often part of a broader oncology strategy.

Patients may experience temporary effects such as mild fatigue or localized discomfort at the treatment site. Some individuals report digestive changes or skin sensitivity during therapy. These effects vary based on individual health and treatment protocols.

Handling requires specialized training due to its radioactive properties. Patients should follow healthcare provider instructions closely to minimize radiation exposure. Pregnant individuals or those with specific sensitivities should avoid direct contact.

No direct drug interactions are reported, but concurrent therapies may influence treatment outcomes. Alcohol and certain supplements could affect overall health during therapy. Always disclose all medications to your healthcare provider before starting.